Substituted benzene compounds
The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
1. A method comprising administering to a subject in need thereof
or
a pharmaceutically acceptable salt thereof at a dosage ranging from about 0.01 mg/kg per day to about 5000 mg/kg per day.
2. The method of claim 1 , wherein the subject has been diagnosed or identified as having cancer or a precancerous condition.
3. The method of claim 2 , wherein the cancer is lymphoma, malignant rhabdoid tumor, a hematological cancer, leukemia, or melanoma.
4. The method of claim 3 , wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), and follicular lymphoma.
5. The method of claim 2 , wherein the cancer is malignant rhabdoid tumor.
6. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the subject is human or non-human mammal.
8. The method of claim 7 , wherein the non-human mammal is a primate, dog, cow, or pig.
9. The method of claim 1 , wherein the subject is a dog.
10. A method comprising administering to a subject in need thereof
or
a pharmaceutically acceptable salt thereof at a dosage ranging from about 0.01 mg/kg per day to about 5000 mg/kg per day.
11. The method of claim 10 , wherein the subject has been diagnosed or identified as having cancer or a precancerous condition.
12. The method of claim 11 , wherein the cancer is lymphoma, malignant rhabdoid tumor, a hematological cancer, leukemia, or melanoma.
13. The method of claim 12 , wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), and follicular lymphoma.
14. The method of claim 11 , wherein the cancer is malignant rhabdoid tumor.
15. The method of claim 10 , wherein the subject is human or non-human mammal.
16. The method of claim 15 , wherein the non-human mammal is a primate, dog, cow, or pig.
17. The method of claim 10 , wherein the subject is a dog.
18. A method comprising administering to a subject in need thereof
or
a pharmaceutically acceptable salt thereof at a dosage ranging from about 0.01 mg/kg per day to about 5000 mg/kg per day.
19. The method of claim 18 , wherein the subject has been previously diagnosed or identified as having cancer or a precancerous condition.
20. The method of claim 19 , wherein the cancer is lymphoma, malignant rhabdoid tumor, a hematological cancer, leukemia, or melanoma.
21. The method of claim 20 , wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), and follicular lymphoma.
22. The method of claim 18 , wherein the cancer is malignant rhabdoid tumor.
23. The method of claim 18 , wherein the subject is human or non-human mammal.
24. The method of claim 23 , wherein the non-human mammal is a primate, dog, cow, or pig.
25. The method of claim 18 , wherein the subject is a dog.